Maintaining Investments in New Innovation Act

This bill extends the exclusivity period for certain advanced drugs from 7 to 11 years. It defines "advanced drug product" as a drug using genetically targeted technology to modulate gene function (e.g., suppress or activate genes). This change directly affects pharmaceutical companies developing these specific advanced therapies by granting them longer market exclusivity. The policy change modifies the Social Security Act to provide extended protection for these innovative drugs, allowing companies more time to recoup research and development costs.